Weight-Loss drug shows promise for pancreatic cancer patients
NCT ID NCT03910387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called telotristat ethyl in 23 people with advanced pancreatic cancer who had lost at least 10% of their body weight. The goal was to see if the drug could help them stabilize or gain weight by reducing bowel movements. Maintaining weight may help patients better tolerate chemotherapy and live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer